VEMBX yields 5.69% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 10
Combined, VEMBX + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VEMBX + JNJ for your $10,000?
This fund seeks to provide total return while generating a moderate level of current income through investing in bonds in emerging economies. Like other bond funds, the fund is subject to interest rate risk; increases in interest rates may cause the price of the bonds in the portfolio to decrease, reducing the fund’s NAV. The fund is also subject to emerging markets risk—bonds in these countries tend to be more volatile and less liquid than those in developed countries—and other international risks, such as country/regional risk. The fund does subject U.S.-based investors to currency risk as it has the ability to invest in local currency denominated bonds on an unhedged basis but the majority of bonds are expected to be invested in in U.S. dollar-denominated bonds or hedged back to the U.S. dollar. Long-term, risk-tolerant investors who want to diversify their bond portfolio may wish to consider this fund.
Full VEMBX Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.